SUSTAINED, TARGETED INVESTMENTS
The amounts invested in R&D by Pierre Fabre's drug and health care division accounts for about 20% of the turnover - a percentage that is higher than the average in this sector, thus reflecting the strategic importance we assign to the availability of new treatment solutions in our priority medical franchises : onco-hematology, dermatology and neuropsychiatry. Our pharmaceutical R&D division employs about 1,000 people.
THREE MAIN AREAS OF RESEARCH
We concentrate our research and development efforts on three therapeutical franchises, in which we have been traditionally involved and enjoy recognized expertise:
When it comes to research, Pierre Fabre has always favored a partnership approach, as it believes that complementarity and sharing of expertise constitute innovation accelerators. Our historical partnership with the French National Center for Scientific Research (CNRS) in the development of vinorelbine (Navelbine®), the first cancer treatment marketed by the company in 1989, epitomizes this approach. For several years, this approach has been structured around partnerships with various French Public Research Institutions (CNRS, INSERM, CEA, etc.), as well as with innovative biotechnology companies (biotechs). This strategy of "open innovation" is intended to provide additional impetus and to accelerate our research and development activities.